CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors

CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors

Aims: To assess prognostic value of pre-therapy carcinoembryonic antigen (CEA) and cytokeratin-19 fragments (CYFRA 21-1) blood levels in non-small cell lung cancer (NSCLC) patients treated with immune-checkpoint inhibitors (ICIs) and their early change as predictor of benefit. Materials and methods:...

Full description

Bibliographic Details
Main Authors: Filippo G. Dall’Olio, Francesca Abbati, Francesco Facchinetti, Maria Massucci, Barbara Melotti, Anna Squadrilli, Sebastiano Buti, Francesca Formica, Marcello Tiseo, Andrea Ardizzoni
Format: Article
Language:English
Published: SAGE Publishing 2020-10-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/1758835920952994

Internet

https://doi.org/10.1177/1758835920952994

Similar Items